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Objectives: This study aims to establish expert
opinion and potential improvements for the Falsified
Medicines Directive mandated medicines authentication
technology.
Design and intervention: A two-round Delphi
method study using an online questionnaire.
Setting: Large National Health Service (NHS)
foundation trust teaching hospital.
Participants: Secondary care pharmacists and
accredited checking technicians.
Primary outcome measures: Seven-point rating
scale answers which reached a consensus of 70–80%
with a standard deviation (SD) of <1.0. Likert scale
questions which reached a consensus of 70–80%, a
SD of <1.0 and classified as important according to
study criteria.
Results: Consensus expert opinion has described
database cross-checking technology as quick and user
friendly and suggested the inclusion of an audio signal
to further support the detection of counterfeit
medicines in secondary care (70% consensus, 0.9
SD); other important consensus with a SD of <1.0
included reviewing the colour and information in
warning pop up screens to ensure they were not
mistaken for the ‘already dispensed here’ pop up,
encouraging the dispenser/checker to act on the
warnings and making it mandatory to complete an
‘action taken’ documentation process to improve the
quarantine of potentially counterfeit, expired or recalled
medicines.
Conclusions: This paper informs key opinion leaders
and decision makers as to the positives and negatives of
medicines authentication technology from an operator’s
perspective and suggests the adjustments which may be
required to improve operator compliance and the
detection of counterfeit medicines in the secondary
care sector.
INTRODUCTION
According to the European Commission, a
falsiﬁed medicine is a fake medicine that
passes itself off as a real authorised medi-
cine;1 according to the Food and Drug
Administration (FDA), a counterfeit medi-
cine is a ‘fake medicine’ that may be contami-
nated or contain the wrong or no active
ingredient. It could have the right active
ingredient but at the wrong dose.2 According
to international intellectual property law, a
‘counterfeit’ is one that infringes a trademark
by bearing an identical or near-identical mark.3
In contrast, the World Health Organization
(WHO) uses the term SSFFC which stands
for substandard, spurious, falsely labelled,
Strengths and limitations of this study
▪ This study is the first of its kind to obtain con-
sensus regarding improvements necessary for
medicines authentication technology, which is a
Pan-European approach to counterfeit medicine
detection; driven by a European directive.
▪ The key consensus improvements for consider-
ation have narrow SDs of ≤1.0.
▪ This study focused on a serialisation and authen-
tication technology provided by one of the three
European Medicines Verification Organisation
‘blueprint providers’.
▪ At the time of research, authentication technol-
ogy was available in only one UK hospital; as
such, the available participants were limited.
▪ This study would require implementation on a
larger sample once suitable participants became
available.
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falsiﬁed and counterfeit medicinal products.4 The
European Medicines Association term of ‘falsiﬁed medi-
cine’ is used in relation with the Falsiﬁed Medicines
Directive (FMD) while the FDA term of counterfeit medi-
cine is used in relation with the Drug Supply Chain
Security Act (DSCSA).
Medicine counterfeiting is a global problem which
requires international action.5 According to the pharma-
ceutical security institute (PSI), there has been a 34%
increase in international drug counterfeiting, illegal
diversion and theft in the last year, and a 51% increase
since 2011.6 Countries around the world have developed
a number of methods to detect counterfeit drugs which
range from laboratory-based and portable Raman
and Quadrupole spectroscopy in developed countries7–10
to SMS messaging in low-income and developing
countries.11
This study assesses serialisation and veriﬁcation tech-
nology, the most rapidly emerging method for detecting
counterfeit medicines. This technological approach has
been adopted in the European Union (EU) under
the FMD12–14 and in the USA under the DSCSA.15
Authentication relates to the veriﬁcation of a medicines
authenticity and subsequent decommissioning using
database cross checking of the medicines unique 12-
digit serial code, at the point of supply to the patient.
Veriﬁcation refers to the scanning of a medicinal
product to identify its status in terms of falsiﬁcation,
expiry or recalled status without decommissioning. The
EU FMD prescribes the systematic serialisation at manu-
facture and authentication at the point of supply to the
patient while the DSCSA requires the veriﬁcation of
medicinal products at each change of ownership without
veriﬁcation or decommissioning at the point of supply
to the patient.
The European Medicines Veriﬁcation Organisation
(EMVO) has described the core principles of authenti-
cation technology and has appointed three blueprint
authentication technology providers for Europe.
These providers are Aegate Holdings Limited, Arvato
Systems GmbH and Solidsoft Reply. Each of these pro-
viders is expected to meet the minimum requirements
as set by the EMVO.16 As only one authentication
technology, provided by Aegate Holdings Limited, was
operational at the time of research, it was chosen to
be integrated into a live secondary care hospital envir-
onment as part of a service evaluation study. On the
scanning and subsequent detection of a recalled,
expired or potentially counterfeit medicine, this tech-
nology presents the user with red or amber pop up
messages which identiﬁes a product as requiring quar-
antine. Medicines authenticated which do not require
quarantine do not generate a pop up but instead gen-
erate a ‘non-action’ symbol. On integration, staff were
trained via presentation and demonstration and also
issued with an authentication protocol which detailed
step by step instructions on how to authenticate
medicines.
The key results from the service evaluation study
related to authentication rates and detection rates of the
technology. Although the technical detection rate of the
technology was 100% and the response rate of the tech-
nology was <300 ms (as mandated by the FMD),13 14 not
all medicines requiring authentication were authenti-
cated and of those authenticated not all of those that
generated a warning pop up were quarantined.17
Following the service evaluations study, this Delphi
method study was conducted to identify the reasons for
poor authentication and detection rates and identify
improvements.
Despite the 2019 legislative technology compliance
deadline for pharmacies, dispensing general practitioner
practices and hospitals across Europe, there is little
qualitative evidence to support this international techno-
logical approach to counterfeit drug detection in prac-
tice. If implemented incorrectly this international
change has the potential to cause considerable upset for
healthcare providers. This study aims to qualitatively
evaluate and inform the optimisation of medicine
authentication technology in secondary care.
A group of 10 secondary healthcare professionals with
experience in medicines authentication were surveyed
following a service evaluation study conducted in 2015,
using the Delphi method approach. The Delphi method
approach, originally used as a systematic forecasting
tool,18 19 has been increasingly used to gain consensus
expert opinion and aid decision-making in a variety of
research areas. Delphi methodology provides clearer
outcomes and recommendations than traditional surveys
often produce, achieved by collecting responses and
summarising responses until a consensus is achieved.
As part of the FMD, policymakers and key opinion
leaders across Europe must come together to form
National Medicines Veriﬁcation Organisations (NMVO).
Each NMVO will make decisions regarding authentica-
tion of technology providers which may relate to func-
tionality, speed of data response, usability and
technology limitations. The study aims to identify the
positives of the incoming technology and educate deci-
sion makers as to the potentially useful technological
changes that could be adopted or mandated as part of
the incumbent medicines authentication technology.
METHODS
Twelve participants from a UK hospital pharmacy
department with experience of using medicines authen-
tication technology as part of a service evaluation
project and satisﬁed the study inclusion and exclusion
criteria (box 1) were invited to take part in a Delphi
method study. An implied consent model was used, with
information regarding the nature of the study contained
in the invitation email18–22 and repeated on the ﬁrst
page of the questionnaire. This information described
the study and its voluntary nature. From a total popula-
tion size of 12, 11 invitations were accepted. One staff
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member was unavailable due to sickness and one staff
member was initially invited inappropriately, as they did
not meet the inclusion criteria. A total of 100% (n=10)
of available eligible participants responded (95% CI)
(2% margin of error).
Prospective participants were asked to complete an
electronic questionnaire18 23 with an estimated comple-
tion time of 15 min or less. Participants received a total
of two questionnaires21 (ie, one for each round of iter-
ation of the questionnaire). The initial invite was fol-
lowed by a number of reminders at ∼8-day intervals until
completion. The question and response format included
three different categories of questions (Box 2), a 7-point
rating scale, a Likert scale and a descriptive or open-
ended response format. Likert scales were used to priori-
tise suggestions. In some cases, the staff identiﬁed four
suggestions and in some cases they identiﬁed ﬁve sugges-
tions, therefore two Likert scales were employed.
Consensus
The 7-point rating scale consensus was achieved when
70% of respondents selected either of two adjacent
answers on a 7-point rating scale24 and the median score
fell within either of the two consensus answers25
(table 1). In terms of the 5-point Likert scale, response
format24 consensus was achieved when 80% of the
respondents selected one of three adjacent answers in
either direction that is, whether participants classed the
suggestion as ‘important’ (1–3) or ‘not important’ (3–
5). On the 4-point Likert scale, the same rules were
applied, however, ‘important’ was classiﬁed as 1–2 and
‘not important’ was classiﬁed as 2–4 with consensus
being achieved when 70% of respondents selected one
of two answers in either direction (table 1). In the case
of a 5-point scale, the median must also have been
below 2.5, and in consideration of a 4-point scale the
median must also have been below 2 to be considered
‘important’19 (table 1).
In terms of the 5-point descriptive/open-ended
response format scale, consensus was assessed depend-
ing on the theme of the response, for example, if 80%
of respondents selected one of three descriptive adja-
cent answers of the same sentiment (positive or nega-
tive) on a 5-point scale, the median score fell within the
consensus category.
The planning of this study was based largely on the
highly cited Hsu and Sandford paper from 2007 which
describes evidence for successful Delphi studies such as
number of survey rounds, consensus ﬁgures and the-
matic analysis.19 Delphi method consensus varied across
studies and opinions differ on a suitable percentage
measure. This study compliments those conducted by
Green in 198224 and Ulschak in 198325 (in Hsu and
Sandford in 2007)19 which promote a consensus of 70
and 80%, respectively. The default consensus in this
study was 70% with 80% used where possible.
SD was chosen as a method to measure central ten-
dencies with an arbitrary <1.0 SD used to supplement
the consensus. This quantiﬁed the spread of responses
across the entire group.
Summary of survey rounds
Round one involved three demographic questions, fol-
lowed by a selection of closed questions relating to
rating scales and performance and open questions
requiring suggestions for a number of improvements,
followed by descriptive questions to evaluate the quality
of the survey. A selection of questions was built on feed-
back from users, during a study which involved the use
of authentication technology for an 8-week period.17
The administration of the second questionnaire was
similar to round one; closed questions that achieved
consensus were removed. Non-consensus questions were
resubmitted to the audience in a rating scale style with
further explanation.
Answers to the open-ended questions in round one
were thematically categorised and summarised to
remove duplicate suggestions. In round two, the experts
were asked to answer further questions based on the
most frequently occurring themes, which included
Box 2 Question and response types
▸ 7-Point Rating Scale (r): This question format rates perform-
ance from 1 to 7, with ‘1’ indicating a negative response and
‘7’ indicating the most positive .The median response was
also gathered for further consensus evaluation.
▸ Likert Scale response format9 (l) : This question style requires
respondents to prioritise suggested improvements in terms of
importance from ‘1’ to ‘4’ or ‘1’ to ‘5’ with ‘1’ indicating most
important and ‘5’ indicating least important (median).
▸ Descriptive/ open-ended response format (d): This response
format does not require prioritisation or rating; rather the ana-
lysis of responses generates a consensus descriptive answer
for the group (median).
Box 1 Inclusion and exclusion criteria for study
participants
Inclusion criteria:
▸ Staff accredited in the professional checking process at the
test site*.
▸ Staff with multiple experiences of using the authentication
technology.
▸ Staff willing to complete multiple surveys.
▸ Staff who have attended basic training as part of the service
evaluation project on medicines authentication.
Exclusion criteria:
▸ Staff who have used the system once or not at all.
▸ Staff who have not passed the trust checking accreditation
test.
*Staff were a mixture of General Pharmaceutical Council-registered
pharmacists and qualified accuracy checking technicians (nationally
recognised qualification).
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Likert scales or descriptive style questions formed as a
direct result of participant suggestions during round
one of the study or during the service evaluation study.17
The total number of suggestions per question varied
between four and ﬁve suggestions which directly affected
the number of options available in round two.
A valid consensus result was considered as ‘achieved’
when consensus had been met and the median scores
also fell within the consensus group (table 1).
Suggestions that fell within these parameters and had a
SD of <1.0 were considered as the most relevant
improvements for the authentication technology. There
was no follow-up with participants after study
completion.
RESULTS
A selection of questions which reached immediate con-
sensus is described in tables 2 and 3. Answers in green
boxes identify the results which reached consensus with
a narrow SD (<1.0). Answers in amber identify a consen-
sus response with a larger SD (>1.0).
The most important suggestions in this study are those
which established consensus among the group (table 1)
with a narrow SD. Improvements included reviewing the
colour and information in warning pop up screens to
ensure they were not mistaken for the ‘already dis-
pensed here’ pop up (2.0) (SD 0.87), encouraging the
dispenser/checker to act on the warnings (2.0) (SD 1.0)
(Education), including an audible alert to accompany
the pop up warning box (1.0) (SD 0.9) (Technology)
and making it mandatory to complete an ‘action taken’
documentation process to improve the quarantine
process for potentially counterfeit, expired or recalled
medicines. (Technology) (2.0) (SD 0.94).
Discussions and recommendations
The serialisation and authentication of medicines has
been proposed in response to international regulation.
Considering that serialisation and veriﬁcation with or
without authentication will affect EU hospital pharma-
cies and is likely to affect US hospitals wishing to whole-
sale supply, it is important to gauge its current
appropriateness and identify improvements in this valu-
able patient safety technology.
There were no concerns regarding the speed and
usability of authentication technology raised during this
study. There was limited impact on the daily activity of
the staff and was classed as ‘not disruptive’. Further
qualitative research would be useful in understanding
Table 1 Summary of consensus
Question type
Consensus





Must fall within the consensus
category










<2 (important) One of three adjacent answers in either direction
Descriptive/open 80%
agreement
Must fall within the consensus
category
One of three adjacent answers of the same sentiment
(positive or negative)
Table 2 A summary of 7-Point Rating Scale results
No Question Result SD
Round 1
4 Based on your experience of the Medicines Authentication System (MAS), how would you rate
its general speed on a scale of 1 to 7? (1 represents very slow and 7 represents very fast)
6/7 0.75
5 Based on your experience of the MAS, how would you describe its usability on a scale of
1 to 7? (1 represents very difficult and 7 represents very easy)
6.5/7 0.87
6 There were some system errors reported by the MAS users throughout the pilot. On a
scale of 1 to 7, how often did you experience these types of errors? (1 represents never
and 7 represents very often) (These errors may have included issues with reading the
two dimensional barcode, duplication of the scan on screen or warnings such as ‘The




7 Question 4: How would you rate the impact of the MAS on the service you provide on a
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why the participants considered this technology as not
disruptive.
The Delphi study identiﬁed a number of suggestions
to improve authentication and detection rates including
the importance of making clear differentiation between
the various warning messages to avoid misinterpretation.
Participants identiﬁed concern with the similarity of
warning messaging which may have had an impact on
the decision to quarantine and may have contributed to
the suboptimal detection rates seen in previous
publications relating to the service evaluation study.17
This study recommends that authentication technology
providers test their technology in a closed loop and real-
life environment prior to national implementation to
ensure that operators respond appropriately to the mes-
saging being displayed.
As with all changes to practice, adequate education and
training is required. There was a basic presentation and
protocol approach used in the service evaluation study17
which may have contributed to inadequate
Table 3 A summary of 4 and 5-Point Likert-like scale results
No Question Result SD
Round 1
7 The following is a list of reported, proposed improvements. Please rank them in order
of importance (1–5).
7 (ii) Change the medicine scanning list on screen to ensure the last scanned item appears
on the top of the list.
1 (Important) 1.25
7 (iv) Review the pop up screens as the Red ‘Warning’ screens could be mistaken for the
common ‘Already dispensed here’ screen.
2 (Important) 0.87
7 (v) Incorporate ‘important information’ pop ups into the authentication system. 2.5 (Important) 1.25
Round 2
5 During round one of this survey, further suggestions were made to improve the
Medicines Authentication System (MAS) or the pilot. Please rank the suggested
changes below in order of importance (1 being most important and 5 being least
important).
(ii) Sounds could also be enabled to ensure warnings/information are noticed (MAS). 2.5 (Important) 1.2
6 During round one of this survey there were a variety of suggestions made to increase
the rate of authentication (scanning). Valid suggestions were subdivided into three
categories 1. process change 2.technology change and 3.education. In terms of
process change, please rank these suggestions in order of importance (with 1 being
the most important and 5 being the least important).
(i) Make the symbol indicating an item that needs to be scanned larger/more visible
(process).
2.5 (Important) 0.92
7 During round one of this survey, there were a variety of suggestions made to increase
the rate of authentication (scanning). Valid suggestions were subdivided into three
categories 1. process change 2. education and 3. technology change. In terms of
education and technology change, please rank these suggestions in order of
importance (with 1 being the most important and 5 being the least important)
(iv) A system change that knows how many items have been booked in and prescription is
not able to be tracked out as verified until all medications have been authenticated
(technology change)
2.5 (Important) 1.2
8 During round one we explained that there have been occasions where products have
been handed out despite showing a pop up warning box. We asked you to list three
suggestions of how this occurrence might be reduced. Valid suggestions were
subdivided into two categories 1. education and 2. technology change. In terms of
education, please rank these suggestions in order of importance (with 1 being the most
important and 4 being the least important)
(i) Encourage the dispenser/checker to take action on the warnings (education) 2.0 (Important) 1.0
9 During round one we explained that there have been occasions where products have
been handed out despite showing a pop up warning box. We asked you to list three
suggestions of how this occurrence might be reduced. Valid suggestions were
subdivided into two categories 1. education and 2. technology change. In terms of
technology change, please rank these suggestions in order of importance (with 1 being
the most important and 4 being the least important)
(ii) An audible alert to accompany the pop up warning box (technology) 1.00 (Important) 0.9
(iii) Making it mandatory to complete an ‘action taken’ documentation process so that staff
scanning are prompted to think about what the red warning means and be accountable
for it (technology)
2.00 (Important) 0.94
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authentication and detection rates due to lack of
adequate support or perhaps due to the sheer volume of
procedures and protocols that staff are required to
adhere to. A practice change of this size may beneﬁt
from a structured training and revalidation package. If we
refer to previous large information technology projects
such as the implementation of the electronic patient
record (EPR), we can see a much more complicated elec-
tronic system with a structured training package which
largely includes presentations, demonstrations, work-
shops, drop-in sessions, protocols and guidance. A varied,
informed and interactive approach, as used in the EPR
project, is required to build operator background knowl-
edge and to instil the clinical and legal importance of
authenticating medicines as well as the impact of authen-
tication on medicine detection rates.
The recent quantitative service evaluation study identi-
ﬁed a disparity between medicines identiﬁed as requir-
ing quarantine and those actually quarantined.17 This
qualitative study demonstrated a consensus that a pop
up warning message alone is not an adequate prompt in
the heterogeneous hospital environment.10 The opera-
tors in this study are in agreement that a noise to indi-
cate a medicine as requiring quarantine is required.
This would remind the operator to act and would also
bring attention to the entire team that a medicine
requiring quarantine had been identiﬁed, generating
peer pressure to act on the warning.
Participants emphasised the importance of an ‘action
taken’ documentation process. Operators relied on
recording the medicine for quarantine on a proforma
located beside the terminal; their view was that this
could be improved with the inclusion of an ‘action
taken’ function incorporated into the authentication
technology software. In a systematic review study by
Shojania et al, the action taken alert has been identiﬁed
as potentially more effective than a ‘non-action’ alert 26
demonstrated in a small group. This ‘action taken’
approach may facilitate an improved detection rate and
may also support a reporting system which would beneﬁt
managerial monitoring of falsiﬁed, counterfeit, recalled
or expired medicines within a department. This would
also allow staff responsible for product quarantine to
tally medicines physically quarantined with medicines
identiﬁed by the technology as requiring quarantine.
Information technology systems such as electronic pre-
scribing or in this case medicines authentication are rela-
tively new approaches to optimise healthcare information.
Shojania et al.26 demonstrate that evidence to support
computer alerts is currently limited. In relation to elec-
tronic prescribing, Shojania concludes by stating ‘Further
research must identify design features and contextual
factors consistently associated with larger improvements in
provider behaviour if computer reminders are to succeed
on more than a trial and error basis’. Further research is
also required in relation to medicines authentication tech-
nology to identify the approaches which facilitate oper-
ational compliance. Hospitals in the NHS vary slightly
depending on the services they provide, which makes
context an important factor in technology success.27
Following on from the remarks made by Shojania et al,
further research is required to understand how contextual
factors can facilitate successful technological projects in
the NHS. One such contextual factor may include incen-
tives to authenticate medicines. The use of reimbursement
codes within the two dimensional data matrix codes is
hypothesised to help the authentication rate of medicines,
a practice seen in the Belgian community pharmacy
setting. There will be a legal mandate to authenticate med-
icines; however, incentives such as reimbursement on
authentication may prove to augment authentication and
detection rates and legal compliance.
The results from this study should inform key opinion
leaders, policymakers and technology manufacturers as
to the limitations of medicines authentication technol-
ogy and potential authentication technology improve-
ments. Considering the limited evidence to support
medicines authentication, the outcomes of this study
should also service decision makers in their discussions
surrounding the selection of medicines authentication
technology providers.
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